Ephedrine Activates Brown Adipose Tissue in Lean but Not Obese Humans

Diabetologia. 2013 Jan;56(1):147-55. doi: 10.1007/s00125-012-2748-1. Epub 2012 Oct 13.

Abstract

Aims/hypothesis: Brown adipose tissue (BAT) activation increases energy consumption and may help in the treatment of obesity. Cold exposure is the main physiological stimulus for BAT thermogenesis and the sympathetic nervous system, which innervates BAT, is essential in this process. However, cold-induced BAT activation is impaired in obese humans. To explore the therapeutic potential of BAT, it is essential to determine whether pharmacological agents can activate BAT.

Methods: We aimed to determine whether BAT can be activated in lean and obese humans after acute administration of an orally bioavailable sympathomimetic. In a randomised, double-blinded, crossover trial, we administered 2.5 mg/kg of oral ephedrine to nine lean (BMI 22 ± 1 kg/m²) and nine obese (BMI 36 ± 1 kg/m²) young men. On a separate day, a placebo was administered to the same participants. BAT activity was assessed by measuring glucose uptake with [¹⁸F]fluorodeoxyglucose and positron emission tomography-computed tomography imaging.

Results: BAT activity was increased by ephedrine compared with placebo in the lean, but unchanged in the obese, participants. The change in BAT activity after ephedrine compared with placebo was negatively correlated with various indices of body fatness.

Conclusions/interpretation: BAT can be activated via acute, oral administration of the sympathomimetic ephedrine in lean, but not in obese humans.

Trial registration: ClinicalTrials.gov NCT01015794.

Publication types

  • Clinical Trial
  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adipose Tissue, Brown / diagnostic imaging
  • Adipose Tissue, Brown / drug effects*
  • Adipose Tissue, Brown / metabolism
  • Adrenergic Agents / pharmacology*
  • Adult
  • Biological Transport / drug effects
  • Body Mass Index
  • Calorimetry, Indirect
  • Cross-Over Studies
  • Double-Blind Method
  • Ephedrine / pharmacology*
  • Fluorodeoxyglucose F18 / analysis
  • Glucose / metabolism
  • Humans
  • Male
  • Multimodal Imaging
  • Obesity / metabolism*
  • Positron-Emission Tomography
  • Sympathomimetics / pharmacology*
  • Thermogenesis / drug effects*
  • Thinness / metabolism*
  • Tomography, X-Ray Computed
  • Young Adult

Substances

  • Adrenergic Agents
  • Sympathomimetics
  • Fluorodeoxyglucose F18
  • Ephedrine
  • Glucose

Associated data

  • ClinicalTrials.gov/NCT01015794